The article discusses research on the use of the drug Truvada as preexposure prophylaxis (PrEP) to prevent HIV transmission. The funding of PrEP is addressed in relation to the previous funding of highly active antiretroviral therapy (HAART) through the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) in low- and middle-income nations. U.S. state policy, as well as plans in Brazil, are noted in relation to PrEP funding for high-risk people.
© 2001-2024 Fundación Dialnet · Todos los derechos reservados